The human beta globin gene domain is flanked by a series of developmentally stable DNase I hypersensitive (HS) sites. Transgenic studies have shown the 5' HS sites to contain elements necessary for high level, regulated expression of globin transgenes. However, the results have been inconclusive concerning the requirement for the 3' HS site. Our investigation of the 3' site (3'HS1) has shown it to be closely linked to scaffold attachment sites, topoisomerase II recognition sequences, several GATA-1 binding sites, and an AP-1/NF-E2 recognition sequence. The combination of structural components and regulatory elements found within 3'HS1 suggest possible regulatory roles for this region. The experiments described in this proposal are designed to determine what role this region plays in the regulation of the beta globin gene domain and how the individual structural components contribute to this regulation. Future attempts at somatic gene therapy as a treatment for sickle cell disease will require a thorough understanding of beta globin regulation.
the specific aims of this proposal are threefold. (1) To identify the subcomponents of 3'HS1. Our preliminary data indicates that 3'HS1 hybridizes to single copy DNA within the mouse genome. I propose to clone and sequence the murine homologue to 3'HS1 and identify those sequences which have been conserved, and presumably important in the regulation of the domain. This approach should complement our transgenic studies and direct the search for important regulatory elements within the region. (2) To determine the biochemical mechanisms for generation of the site. Footprinting experiments will be used to identify DNA/protein interactions within the region. Specific binding sites will be altered by site-directed mutagenesis or deleted in their entirety, incorporated into beta globin transgenes, and the consequences of these changes monitored in transgenic mice and/or MEL cells. Genomic sequences shown to bind nuclear proteins will be used to probe cDNA expression libraries in order to identify the genes which encode the trans-acting nuclear proteins. (3) To determine the role of 3'HS1. Beta globin transgenes containing 3'HS1, either alone or in combination with the activating 5' LCR will be introduced into transgenic mice and MEL cells and their expression monitored by primer extension. Once we establish the function of 3'HS1, deletional analysis of the region will be used to determine the minimum sequences required.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Comprehensive Center (P60)
Project #
5P60HL028391-14
Application #
5213383
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
14
Fiscal Year
1996
Total Cost
Indirect Cost
Ariens, Robert A S; Lai, Thung-Shenq; Weisel, John W et al. (2002) Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood 100:743-54
Ware, Russell E; Eggleston, Barry; Redding-Lallinger, Rupa et al. (2002) Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood 99:10-4
Thompson Jr, Robert J; Gustafson, Kathryn E; Bonner, Melanie J et al. (2002) Neurocognitive development of young children with sickle cell disease through three years of age. J Pediatr Psychol 27:235-44
Slaughter, T F; Sreeram, G; Sharma, A D et al. (2001) Reversible shear-mediated platelet dysfunction during cardiac surgery as assessed by the PFA-100 platelet function analyzer. Blood Coagul Fibrinolysis 12:85-93
Lai, T S; Hausladen, A; Slaughter, T F et al. (2001) Calcium regulates S-nitrosylation, denitrosylation, and activity of tissue transglutaminase. Biochemistry 40:4904-10
Ataga, K I; Orringer, E P (2000) Renal abnormalities in sickle cell disease. Am J Hematol 63:205-11
Ataga, K I; Orringer, E P (2000) Bone marrow necrosis in sickle cell disease: a description of three cases and a review of the literature. Am J Med Sci 320:342-7
Kinney, T R; Helms, R W; O'Branski, E E et al. (1999) Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 94:1550-4
Lai, T S; Slaughter, T F; Peoples, K A et al. (1999) Site-directed mutagenesis of the calcium-binding site of blood coagulation factor XIIIa. J Biol Chem 274:24953-8
Slentz-Kesler, K A; Hale, L P; Kaufman, R E (1998) Identification and characterization of K12 (SECTM1), a novel human gene that encodes a Golgi-associated protein with transmembrane and secreted isoforms. Genomics 47:327-40

Showing the most recent 10 out of 78 publications